Related references
Note: Only part of the references are listed.Uncertain resection of highest mediastinal lymph node positive among pN2 non-small cell lung cancer patients: survival analysis of postoperative radiotherapy and driver gene mutations
Qianyue Deng et al.
JAPANESE JOURNAL OF RADIOLOGY (2023)
The impact of postoperative radiotherapy on the survival of patients with stage III non-small cell lung cancer: A CONSORT-compliant analysis using the SEER database
Kun Wu et al.
MEDICINE (2023)
Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer
Antonin Levy et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial
Cecile Le Pechoux et al.
LANCET ONCOLOGY (2022)
Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis
Barbara Melosky et al.
MOLECULAR DIAGNOSIS & THERAPY (2022)
Lung Cancer Epidemiology and Screening
Aundrea L. Oliver
SURGICAL CLINICS OF NORTH AMERICA (2022)
Optimal positive lymph node ratio showing the benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: an exploratory study using the Surveillance, Epidemiology, and End Results data
Shiho Lee et al.
RADIATION ONCOLOGY JOURNAL (2022)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines
Alireza Mardanshahi et al.
MOLECULAR BIOLOGY REPORTS (2021)
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy The Phase 3 PORT-C Randomized Clinical Trial
Zhouguang Hui et al.
JAMA ONCOLOGY (2021)
Complete Resection in Lung Cancer Surgery: From Definition to Validation and Beyond
Ramon Rami-Porta et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer
J. Jin et al.
CURRENT ONCOLOGY (2020)
The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer
Chongze Yuan et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
Lymphovascular Invasion Increases the Risk of Nodal and Distant Recurrence in Node-Negative Stage I-IIA Non-Small-Cell Lung Cancer
Soo Yoon Sung et al.
ONCOLOGY (2018)
Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach
Weiye Deng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number
Siwei Wang et al.
RADIATION ONCOLOGY (2017)
Postoperative radiotherapy for lung cancer: Is it worth the controversy?
Charlotte Billiet et al.
CANCER TREATMENT REVIEWS (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection
Changhoon Yoo et al.
CLINICAL LUNG CANCER (2015)
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non-Small-Cell Lung Cancer
Damien Urban et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians
Wei Zhou et al.
Chinese Journal of Cancer (2011)
Prognostic Factors for Resected Non-Small Cell Lung Cancer with pN2 Status: Implications for Use of Postoperative Radiotherapy
Luigi Moretti et al.
ONCOLOGIST (2009)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)